Detalhe da pesquisa
1.
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
Ann Oncol
; 35(3): 248-266, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38307807
2.
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Ann Oncol
; 33(10): 1021-1028, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35772665
3.
The systemic treatment of recurrent ovarian cancer revisited.
Ann Oncol
; 32(6): 710-725, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33675937
4.
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Ann Oncol
; 31(12): 1606-1622, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33004253
5.
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
Gynecol Oncol
; 159(3): 692-698, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33077258
6.
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Gynecol Oncol
; 159(2): 442-448, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32981695
7.
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Ann Oncol
; 30(7): 1080-1087, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31046082
8.
Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
Ann Oncol
; 29(6): 1366-1376, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29750420
9.
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ann Oncol
; 34(10): 833-848, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37597580
10.
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
Ann Oncol
; 34(1): 33-47, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36307055
11.
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
Ann Oncol
; 29(2): 431-438, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29186319
12.
Front-line therapy of advanced ovarian cancer: new approaches.
Ann Oncol
; 28(suppl_8): viii46-viii50, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29232475
13.
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ann Oncol
; 33(9): 860-877, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35690222
14.
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.
Ann Oncol
; 28(4): 711-717, 2017 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28327917
15.
PARP inhibitors in ovarian cancer.
Ann Oncol
; 27 Suppl 1: i40-i44, 2016 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27141070
16.
Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines.
Ann Oncol
; 32(10): 1300-1303, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34293462
17.
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.
Ann Oncol
; 26(10): 2034-43, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26063635
18.
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
Ann Oncol
; 25(1): 32-40, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24225019
19.
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.
Ann Oncol
; 25(10): 1988-1995, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25070546
20.
Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.
Ann Oncol
; 25(8): 1616-22, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24827136